Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05361577
Other study ID # 2021-A01668-33
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date July 31, 2023

Study information

Verified date December 2023
Source Institut De La Colonne Vertebrale Et Des Neurosciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fibromyalgia is a debilitating pain condition that is characterized by the chronic occurrence of pain affecting the musculoskeletal system, a sensitivity to pressure stimuli, and a low threshold to noxious stimuli. The topography of pain is widespread, although it could be more pronounced in some bodily regions. Besides pain, patients suffer from a wide range of symptoms, including fatigue, anxiety and depression manifestations, and altered quality of life. Facing these debilitating symptoms, the available therapeutic strategies for treating pain and associated manifestations are usually faced with limited efficacy and numerous side effects. For these reasons, non-invasive stimulation techniques, namely transcutaneous stimulation by means of Exopulse Mollii suit, might be of help in this context. The investigators designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of "active" versus "sham" Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date July 31, 2023
Est. primary completion date July 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients aged between 18 and 75 years, with a definite diagnosis of fibromyalgia according to the American College of Rheumatology (ACR) 2010 criteria, set for at least one month - Patients should be French speakers, able to understand verbal instructions, and affiliated to the national health insurance Exclusion Criteria: - Patient with VAS < 4 - Patient included in another research protocol during the study period - Patient unable to undergo medical monitor for the study purposes due to geographical or social reasons - Patient with contraindication to wearing Exopulse Mollii suit (e.g., cardiac stimulator, a ventriculoperitoneal shunt, intrathecal baclofen pump, pregnancy, and/or body mass index above 35 kg/m2) - Patient with other somatic or psychiatric diagnoses other than anxiety and depression (e.g., arrhythmias, uncontrolled epilepsy, other diseases causing osteoarticular and muscular pain) - Any change in the pharmacological therapy in the last three months - Introduction of a medical device other than Exopulse Mollii suit during the study period - Patient under juridical protection (" mesure de protection judiciare : tutelle, curatelle, sauvegarde de justice ")

Study Design


Intervention

Device:
Exoplulse Mollii suit
Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
Exopulse Mollii suit (sham)
In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.

Locations

Country Name City State
France Hopital Henri Mondor Créteil

Sponsors (1)

Lead Sponsor Collaborator
Institut De La Colonne Vertebrale Et Des Neurosciences

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Visual Analogue Scale for Pain VAS consists of rating the symptom on a 10 cm horizontal line going from "no pain" to "worst pain imaginable". This be assessed at baseline (before intervention) then at 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks later
Secondary Pain Catastrophizing Scale (PCS) Pain Catastrophizing Scale (PCS) will be employed, which is a valid and reliable scale that includes 13 items assessing the presence and severity of feelings or thoughts that emerge when experiencing pain. Each item is rated on a 5-point Likert scale ranging from 0 (not at all) to 4 (all the time). It is possible to calculate a total and three subscale scores (i.e., helplessness, magnification, and rumination) This be assessed at baseline (before intervention) then at 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks later
Secondary Brief Pain Inventory The validated French version of the Brief Pain Inventory (BPI) will be used to assess pain severity (4 items) and pain interference (7 items). BPI items are rated on a 10-point scale running from 0 (no pain/does not interfere) to 10 (pain as bad as the participant can imagine/interferes completely). This be assessed at baseline (before intervention) then at 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks later
Secondary Visual Analogue Scale (VAS) for fatigue Like pain, fatigue will be assessed using VAS which consists of rating the symptom on a 10 cm horizontal line going from "no fatigue" to "worst fatigue imaginable". This be assessed at baseline (before intervention) then at 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks later
Secondary Fibromyalgia Impact Questionnaire (FIQ) It is an 11-item scale that assesses health status and functional disability by exploring the impact of fibromyalgia on work, wellbeing, fatigue, sleep, stiffness, anxiety, and depression. FIQ scores can range from 0 to 100, with higher scores reflecting worse health status. Scores could be used to classify fibromyalgia as mild (scores: 0-38), moderate (scores: 39-58), and severe (scores: 59-100) This be assessed at baseline (before intervention) then at 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks later
Secondary Hospital Anxiety and Depression Scale (HADS) It is a 14-item generic scale with good psychometric properties and consists of seven items assessing anxiety and seven others assessing depression. Scores can range from 0 to 21 on each subscale, with higher scores indicating worse symptomatology This be assessed at baseline (before intervention) then at 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks later
Secondary Short Form 36 Health Survey (SF-36) It is a generic survey that contains 36 items which assess the quality of life and yield eight dimensions: physical functioning, physical role, emotional role, bodily pain, general health, vitality, social functioning, and mental health. The score of each dimension ranges from 0 to 100, with higher scales implying better health status. This be assessed at baseline (before intervention) then at 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks later
See also
  Status Clinical Trial Phase
Completed NCT03149198 - Mat Pilates Method in the Treatment of Women With Fibromyalgia N/A
Completed NCT00965081 - A Study for Adult Patients With Fibromyalgia Phase 4
Enrolling by invitation NCT06100926 - Effectiveness of Virtual Reality (VR) in Non-oncologic Chronic Musculoskeletal Pain N/A
Recruiting NCT05068791 - Psilocybin-facilitated Treatment for Chronic Pain Early Phase 1
Recruiting NCT05801497 - Balneotherapy in Primary Fibromyalgia
Active, not recruiting NCT04422522 - Fibromyalgia During the COVID-19 Pandemic
Recruiting NCT05754190 - Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
Recruiting NCT05941780 - Pain Phenotypes in Patients With Fibromyalgia Syndrome
Not yet recruiting NCT06424743 - Preference of Women With Fibromyalgia Undergoing a Three Different Volumes of Resistance Training N/A
Completed NCT04771260 - Understanding Health Services Delivery for Fibromyalgia
Active, not recruiting NCT04690400 - Telehealth Stretching Exercise Program for Women With Fibromyalgia During the Covid-19 Pandemic N/A
Recruiting NCT05644054 - The Impact of THC on Pain Modulation in Fibromyalgia N/A
Enrolling by invitation NCT04098757 - Fibromyalgia Different Approaches: Acupuncture vs Migratens
Completed NCT01697254 - The CARRA Registry N/A
Completed NCT00678691 - An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Phase 4
Recruiting NCT04832100 - Bio-significance of LPC16:0 in Fibromyalgia
Not yet recruiting NCT05688787 - Efficacy of Perineural Injection Therapy in Primary Fibromyalgia N/A
Completed NCT03905486 - Efficacy of Pregabalin Versus Combined Pregabalin and Milnacipran in Fibromyalgia. N/A